Please note: Due to the pandemic-related plasticware shortage, the plastic packaging of products may be subject to changes.
Such package changes do not affect the quality of our products.

StemMACS™ HSC-CFU Media, human

StemMACS HSC-CFU Media have been developed for the expansion of CD34
+
cells and to assess the differentiation potential of human hematopoietic stem and progenitor cells as Colony Forming Units (CFU). They are ideally suited for use with
  • unseparated blood3, bone marrow4, or fetal liver cells
  • sorted cell populations1,4
  • or ES and iPS cell-derived hematopoietic precursors2

Specifications for StemMACS™ HSC-CFU Media, human

Overview

StemMACS HSC-CFU Media have been developed for the expansion of CD34
+
cells and to assess the differentiation potential of human hematopoietic stem and progenitor cells as Colony Forming Units (CFU). They are ideally suited for use with
  • unseparated blood3, bone marrow4, or fetal liver cells
  • sorted cell populations1,4
  • or ES and iPS cell-derived hematopoietic precursors2

Detailed product information

StemMACS HSC-CFU Media are standardized semi-solid media based on methylcellulose in IMDM, supplemented with FBS, BSA, and different growth factors. StemMACS HSC-CFU media are designed to maximize growth and differentiation of progenitor cells and allow the clonal progeny of a single cell to grow in a distinct cluster or colony. They are produced under tightly controlled manufacturing conditions and use highly qualified raw materials to provide a consistent and optimally performing colony assay.
StemMACS HSC-CFU media are available in different formats.
Online tutorial to perform the standard HSC-CFU assay

Technical data

Formulation of StemMACS HSC-CFU media
Formulation of StemMACS HSC-CFU media

References for StemMACS™ HSC-CFU Media, human

Publications

  1. Liedtke, S. et al. (2020)
    GMP‐grade CD34
    +
    selection from HLA‐homozygous licensed cord blood units and short‐term expansion under European ATMP regulations.
    Vox sang. (doi: 10.1111/vox.12978)
  2. Venton, G. et al. (2016) Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors. Blood Cancer J. 6(9): 469
  3. Liu, G.-H. et al. (2014) Modelling Fanconi anemia pathogenesis and therapeutics using integration-free patient-derived iPSCs. Nat Commun. 5: 4330
  4. Brault, J. et al. (2014)
    Optimized generation of functional neutrophils and macrophages from patient-specific induced pluripotent stem cells:
    ex vivo
    models of X
    0
    -linked, AR22
    0
    - and AR47
    0
    - chronic granulomatous diseases.
    Biores Open Access 3(6): 311-326
  5. Bissels, U. et al. (2011)
    Combined characterization of microRNA and mRNA profiles delineates early differentiation pathways of CD133
    +
    and CD34
    +
    hematopoietic stem and progenitor cells.
    Stem Cells 29: 847-857
  6. Tormin, A. et al. (2011)
    CD146 expression on primary nonhematopoietic bone marrow stem cells is correlated with
    in situ
    localization.
    Blood 117: 5067-5077
  7. Zhou, J. et al. (2011) The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood 118: 2830-2839
  8. Lambert, J. R. et al. (2009)
    In essential thrombocythemia, multiple
    JAK2
    -V617F clones are present in most mutant-positive patients: a new disease paradigm.
    Blood 114: 3018-3023
  9. Watts et al. (2008) Cytotherapy 10(suppl. 1): poster no. 150
  10. Biedermann, B. et al. (2007) Analysis of the CD33-related siglec family reveals that Siglec-9 is an endocytic receptor expressed on subsets of acute myeloid leukemia cells and absent from normal hematopoietic progenitors. Leuk. Res. 31: 211-220
  11. Chang, K. H. et al. (2006) Definitive-like erythroid cells derived from human embryonic stem cells coexpress high levels of embryonic and fetal globins with little or no adult globin. Blood 108: 1515-1523
  12. Del Fante, C. et al. (2005)
    Immunomagnetic cell selection performed for HLA haploidentical transplants with the CliniMACS device: effect of additional platelet removal on CD34
    +
    cell recovery.
    Stem Cells Dev. 14: 734-739

Related products for
StemMACS™ HSC-CFU Media, human

7 products available | view all
 

StemMACS™ HSC-CFU Assay Kit, human

StemMACS™ HSC-CFU Assay Kit has been developed for the expansion of CD34+ cells and the evaluation ...

 

CD34
+
CD38
-
Cell Isolation Kit
, human

The CD34+CD38– Cell Isolation Kit, human has been developed to isolate a CD38– subset of CD34+ cell ...

 

CD34 MicroBead Kit UltraPure, human

The CD34 MicroBead Kit UltraPure is the latest development for positive selection of CD34+ ...

 

CD133 MicroBead Kit, human

The CD133 MicroBead Kit allows basic isolation or depletion of CD133+ cells from various sources ...

Seems like you are coming from USA!
Do you want to visit our website in your country?

Copyright © 2023 Miltenyi Biotec and/or its affiliates. All rights reserved.